Our pipeline
At Ryvu Therapeutics, we are advancing a robust pipeline focused on addressing emerging and critical targets in oncology.
Our pipeline features candidates with unique therapeutic mechanisms, targeting key areas such as kinase pathways, synthetic lethality, and immuno-oncology. These innovative programs are designed to offer targeted solutions for challenging cancers, providing hope for better patient outcomes.
Clinical & Preclinical Programs
program
indication
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
RVU120 (CDK8/19)
indication
RIVER-81
R/R AML
(combo with venetoclax)
discovery
PRECLINICAL
PHASE I
PHASE II
indication
POTAMI-61
Myelofibrosis
(mono and combo with ruxolitinib)
discovery
PRECLINICAL
PHASE I
PHASE II
indication
RIVER-52R/R AML/HR-MDS
(monotherapy - enrollment suspended)
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
Dapolsertib(PIM/FLT3)
indication
JASPIS-01
DLBCL
(mono and combo with glofitamab)
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
RVU305 (MTA-cooperative PRMT5)
indication
MTAP-deleted tumors
discovery
PRECLINICAL
PHASE I
PHASE II
Publications
- pdf file
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Download - pdf file
Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers
Download - pdf file
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
Download - pdf file
Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells
Download
- pdf file
Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment
Download - pdf file
Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies
Download